2021-11-01 - Cancer Synoptic Reporting Project Group Meeting

1

Status of initial sub

@Scott Campbell

• Confirm date of 2021-10-31 availability

2

Intactness/quality of specimen concepts

@Scott Campbell

1. Discuss representation of "intactness" and specimen quality (colon, ovary, thyroid)
   
   
   

2. Confirm Business Meeting Conclusion

Approach agreed upon.  Create new concept |Anatomic integrity (property)|.  When used with |Inheres in| = some (specimen), then the discussion is about the anatomic integrity of the specimen which is appropriate for CSRWG observations.

When used with |Inheres in| = some (body structure), the discussion is about the anatomic integrity of the body structure as is the case discussed pertaining to in vivo observations.

3

Mitotic rate

@Scott Campbell

1. What phase(s)

number cell in Cell division phase phase/total count of cells in a normalized area

1. Mitotic rate = count/area = > #mitoses/area

2. Ki-67=> proliferation fraction...# cells expressing ?/total count in a specific area  mitotic cell state/resting state

4

Metastasis observable

@Scott Campbell

Inclusion of primary tumor site in observable as |Inherent location| in metastatic spread observables

Review sample concept

So far, so good.  More to model and synchronize with morphologic abnormality plan for primary/secondary neoplasm.

5

Tumor Deposit

@Scott Campbell

Review model for colon and appendix

Discuss with # of Tumor Deposits

6

Microsatellites/tumor nodules

@Scott Campbell

Melanoma

7

Tumor descriptions

@Scott Campbell

Tumor description (adrenal); Rhabdoid; Sarcomatoid (kidney); histologic patterns (lung)

These are dedifferentiation descriptors.  Need to review ICD-O-3.2 to see if they are histologic subtypes vs. structural/proliferation/differentiation description

8

Lymph node locations/stations

@Scott Campbell

Discuss approach to lymph node body structures and differences in naming/locations (example AJCC esophageal cancer vs. JES esophageal cancer)

9

IHC

@Scott Campbell

Model review and discussion

ER, PR, Her2, Ki-67, PD-L1, MLH1, PMS2, MSH2, MSH6,ATRX expression, Beta-catenin expression, reticulin

How are these broken out/logically organized?  Nuclear proteins? Cytoplasmic: Receptors?

10

Communication to users

@Scott Campbell

Strategies to communicate work products?

Did not discuss

11

Tumor Staging

@Daniel Karlsson @Scott Campbell

Discussed use of TNM-category levels....

AJCC wants SI to eliminate all  TNM content from terminology.

UICC may be an alternative.

@Daniel Karlsson to discuss at member forum next week (26-10-2021)

What are use cases?  

CDSS, research, electronic data exchange between systems...